Abstract: Introduction: The geographical distribution of Behcet's Disease (B.D) is thought to be due to the predisposing factor(s) spread along the Silk Route. It is widely accepted that the predisposing factor(s) is of genetic origin. However the rarity of BD among Hawaiian's Japanese immigrants may be in favor of environmental factors. Iran is situated in the middle of the Silk Route. Caucasians account for 75.4%, Turks (from Mongoloid ethnic origin) for ...
Familial Oral Aphthosis in General Population As Compared To Behcet’s Disease.
Abstract: Introduction: Oral aphthosis (OA) is seen in 96% of patient with Behcet’s Disease (BB) OA is said to be rather frequent in the general population. It was therefore interesting to determine whether OA in the general population had also a genetic background as it is for BD. It was also interesting to determine if the genetic background was similar in both conditions (BD and OA in the general population). Therefore, ...
METHOTREXATE FOR OCULAR LESIONS OF BEHCET'S DISEASE. COHORT STUDY ON 262 PATIENTS.
Abstract: INTRODUCTION: Ocular lesions of Behcet's Disease (BD) progress usually toward severe loss of vision or blindness, if not aggressively treated. Cytotoxic drugs are the main therapeutic arsenals used for it: Low dose methotrexate (MTX) by its safety and its efficacy is one of the best therapeutic choices. MATERIALS &METHODS: MTX was used as 7.5 mg weekly. Prednisolone was associated as 0.5 mg/kg/ daily. Upon the suppression of the inflammatory reaction, prednisolone ...
Pulse Cyclophosphamide for ocular Manifestations of Behcet's Disease. Cohort study on 283 patients.
Abstract: Introduction: Posterior uveitis (PU) and retinal vasculitis (RV) usually progress toward severe loss of vision or blindness, if not aggressively treated. The aim of this study is to evaluate the efficacy of Pulse Cyclophosphamide (PCP) in a cohort study. Methods: This study includes all patients treated with PCP from 1986 to 1998, for active PU and or RV. PCP was administered as Ig cvclophosphamide/m2/body surface, once per month. Prednisolone was given ...
BEHCET'S DISEASE – ANALYSIS OF 3443 CASES.
Abstract: Behcet's Disease (BD) is classified among the Vasculitides. It is characterized by mucocutaneous and ophthalmologic manifestations and seen mostly in the Northern Hemisphere and in countries along the silk road. The characteristics of BD are presented here in a nation wide analysis of 3443 patients in Iran over a 21 year period. There was a slight male preponderance M.F ratio 1.4:1 (53.3% male/46.7% female). The mean age of onset was ...
Outcome of Patients With Ocular Lesions of Behcet's Disease (BD) Non Responding to Classical Treatments.
Abstract: Introduction: We reported last year, during the ACR annual meeting, the result of different treatment modalities for ocular lesions of BD in 856 patients. We showed that pulse cyclophosphamide (PCP), low dose pulse cyclophosphamide (LDP), oral cyclophosphamide (OCP), weakly methotrexate (MTX), chloambucil (CHL), and cyclosparine A (CYA) had all the same efficacy. The percentage of the eyes aggravated (visual acuity) despite the treatment was: For PCP: 21%, LDP: 22%, OCP: ...
APLAR validation of Behcet’s disease (BD) diagnosis criteria, Iran experience.
Abstract: Considering that the majority of BD patients are from APLAR (Asia and Pacific League of Associations for Rheumatology) countries any diagnosis criteria for BD must have an adequate accuracy in these countries. The APLAR subcommittee for Behcet's Disease has set a prospective study to assess the accuracy of the existing diagnosis criteria. China, Iran, Japan, and Korea, the major countries with BD are participating to this study. The data from ...
Outcome analysis of ocular lesions in Behcet’s disease with six different therapeutic methods.
Abstract: Introduction: Ocular lesions are the major cause of morbidity in Behcet's Disease. If not treated, they usually progress toward severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic arsenal used for this condition. Materials & Methods: in an open, non randomized control study. Pulse Cyclophosphamida (PCP), low dose pulse cyclophosphamide (LDP), oral cyclophosphamide (OCP). weakly methotrexate (MTX), chlorambucil (CHL), and cyclosporine A (CYA) were used in a standard ...
Behcet’s disease treatment.
Abstract: There is not yet an effective treatment for all lesions of Behcet's disease and for all patients with Behcet's disease. The highest morbidity is from the ocular lesions. The mortality, although rare, is due to neurological and pulmonary involvement. Thrombosis of the large veins and arteries, also rare, may lead to morbidity and mortality. In daily practice, the best treatment for muco cutaneous lesions is colchicine. Thalidomide may be efficient ...
Outcome measurement of ocular lesions in Behcet’s disease.
Abstract: The outcome of ocular manifestations of Behcet’s Disease remains uncertain and unpredictable despite cytotxic drugs. One of our recent studies, presented to the 1995 Korean Rheumatology Annual Meeting, showed that one third of patients were None Responders, regardless of what treatment used. This study was designed to search for factors predicting the final outcome at the beginning of the treatment. Patients having more than one year of treatment were selected ...